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Abstract: Antimicrobial resistance is a global concern. Over the past few years, consider-
able efforts and resources have been expended to detect, monitor, and understand at the basic 
level the many different facets of emerging and increasing resistance. Development of new 
antimicrobial agents has been matched by the development of new mechanisms of resistance 
by bacteria. Current antibiotics act at a variety of sites within the target bacteria, including the 
cross-linking enzymes in the cell wall, various ribosomal enzymes, nucleic acid polymerases, 
and folate synthesis. Ceftobiprole is a novel parenteral cephalosporin with high affinity for most 
penicillin-binding proteins, including the mecA product penicillin-binding protein 2a, rendering 
it active against methicillin-resistant staphylococci. Its in vitro activity against staphylococci and 
multiresistant pneumococci, combined with its Gram-negative spectrum comparable to that of 
other extended-spectrum cephalosporins, its stability against a wide range of beta-lactamases, 
and its pharmacokinetic and safety profiles make ceftobiprole an attractive and well tolerated 
new antimicrobial agent. The US Food and Drug Administration granted ceftobiprole medocaril 
fast-track status in 2003 for the treatment of complicated skin infections and skin structure 
infections due to methicillin-resistant staphylococci, and subsequently extended this to treatment 
of hospital-acquired pneumonia, including ventilator-associated pneumonia due to suspected 
or proven methicillin-resistant Staphylococcus aureus.
Keywords: ceftobiprole, methicillin-resistant staphylococci, skin infection, hospital acquired 
pneumonia
Introduction
Since the introduction of antimicrobial agents in the 1940s, antibiotic resistance has 
become an increasing problem. Today, multiple-antibiotic resistance is commonly 
associated with a number of clinically important pathogens. Four general mechanisms 
of resistance have been shown. Target site alterations, inactivation of antimicrobials, 
alterations in cell wall permeability that deny access to antimicrobials and efflux 
mechanisms that pump the antimicrobial out of the cell before it can reach its target 
site. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a cause 
of infection not only in healthcare settings but also in the community. Skin and 
soft tissue infections are most common, but invasive manifestations also occur. 
Strains of MRSA circulating in the community generally are susceptible to a number 
of non beta-lactam antimicrobial agents, although resistance patterns may vary 
temporally and geographically. Ceftobiprole, the active principle of the water-soluble 
prodrug BAL 5788 is a novel parenteral cephalosporin with high affinity for most 
penicillin-binding proteins (PBP), including the mecA product PBP2a, and stability Infection and Drug Resistance 2010:3 
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to almost all class A and C beta-lactamases.1 Ceftobiprole 
is currently undergoing evaluation by the US Food and 
Drug Administration for the treatment of complicated skin 
and skin structure infections and community-acquired and 
healthcare-associated pneumonia. Two Phase III multicenter 
trials2,3 have demonstrated non-inferiority in complicated skin 
and skin structure infections when tested against vancomycin 
in primarily Gram-positive bacterial infections, and when 
tested against vancomycin plus ceftazidime in Gram-positive 
and Gram-negative bacterial infections. Two other Phase III 
clinical trials to assess ceftobiprole’s efficacy in community-
acquired pneumonia and nosocomial pneumonia have also 
concluded. While the drug met the non-inferiority criteria for 
community-acquired pneumonia and nosocomial pneumonia 
involving non-ventilator associated pneumonia, ceftobiprole 
was less effective than the comparator in ventilator associated 
pneumonia subjects.4
In vitro antibacterial activity: 
ceftobiprole and the  
penicillin-binding proteins (PBP)
Ceftobiprole is a new member of the pyrrolidinone-
3-ylidenemethyl cephem series of cephalosporins. The 
antibacterial effects of ceftobiprole are mediated through 
blockage of the final steps of cell wall (peptidoglycan) 
biosynthesis.5 Ceftobiprole exhibits potent binding to PBPs 
from Gram-positive bacteria, including those with decreased 
beta-lactam sensitivity, such as PBP2a in MRSA (unlike 
ceftriaxone and ceftazidime), and PBP2x (the primary 
cephalosporin targets) in penicillin-resistant Streptococcus 
pneumoniae (ceftobiprole had an eight fold-higher 
binding affinity for a mutated PBP2x than ceftriaxone).6 
In Escherichia coli, ceftobiprole exhibits strong binding 
to PBP2 and PBP3 (the primary targets for monobactams 
and most cephalosporins). Ceftobiprole exhibits a binding 
profile similar to those of cefepime and ceftazidime in 
Pseudomonas aeruginosa but with an enhanced binding 
to PBP2.6 This profile contributes to the broad-spectrum 
antibacterial activity against gram-negative and gram-
positive bacteria of this cephalosporin. No breakpoints 
have been established for ceftobiprole, but based on 
minimum inhibitory concentration (MIC) distribution and 
pharmacokinetic/pharmacodynamic information, Mouton 
et al7 proposed a provisional breakpoint of 4 µg/mL 
for susceptible Gram-positive microorganisms. This 
breakpoint may not be applicable to Gram-negative 
bacteria. The Clinical and Laboratory Standards Institute 
has published acceptable limits for quality control strains 
for disk diffusion and MIC testing.8,9
Spectrum of activity
Ceftobiprole is active against S. aureus, including 
MRSA and vancomycin-intermediate S. aureus (VISA), 
coagulase-negative staphylococci (CNS), Enterococcus 
species (including vancomycin-resistant but not ampicillin-
resistant enterococci), pneumococci, some anaerobes, and 
Gram-negative bacilli (with similar activity to third- and 
fourth-generation cephalosporins, with the exception of 
Proteus vulgaris).5,10–14 Ceftobiprole is not active against 
extended-spectrum beta-lactamase (ESBL) producing strains 
of Enterobacteriaceae.13,15,16 Published MIC data for a range 
of microorganisms are shown in Table 1.
Staphylococcus species
Ceftobiprole has showed consistent activity against 
staphylococci in several studies with MICs for methicillin-
resistant staphylococci higher than those for methicillin-
susceptible staphylococci. In vitro activity against 
methicillin-resistant staphylococci appears to be a particu-
larly valuable asset of this novel cephalosporin. The anti-
staphylococcal activity of ceftobiprole was comparable to 
that of linezolid in one study.17 Ceftobiprole was shown to 
inhibit MRSA at 4 µg/mL.15 In this study, the higher cefto-
biprole MIC values for S. haemolyticus and S. saprophyticus 
are consistent with those reported in another studies.18,19 Jones 
et al20 tested ceftobiprole against 262 isolates of Staphylo-
coccus species using agar dilution. All ceftobiprole MIC 
values were 2 µg/mL for 146 isolates of S. aureus includ-
ing MSSA (MIC90, 1 µg/mL) and MRSA (MIC90, 2 µg/mL). 
Denis et al6 reported ceftobiprole MIC50 and MIC90 values of 
0.5 and 2 µg/mL, respectively against MRSA. Of a total of 
1201 S. aureus (66% MRSA) and 460 CNS single-patient 
isolates, ceftobiprole MICs ranged from 0.12 to 1 µg/mL 
for MSSA and 0.25 to 4 µg/mL for MRSA.18 Ceftobiprole 
was active against 15,067 staphylococci isolates, inhibiting 
100% of S. aureus and CNS at 4 and 8 µg/mL, respec-
tively, although MIC90 values of oxacillin-resistant isolates 
were 4- and 8-fold higher than those of oxacillin-susceptible 
isolates.21 Rouse et al22 showed that ceftobiprole had inhibi-
tory activity similar to that of daptomycin, linezolid and 
vancomycin, and bactericidal activity similar to that of 
daptomycin and vancomycin against 37 isolates of MRSA 
and 51 isolates of methicillin-resistant CNS recovered 
from patients with endocarditis, and 31 isolates of MRSA 
and 65 isolates of methicillin-resistant coagulase-negative Infection and Drug Resistance 2010:3 
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Table 1 Antimicrobial activity of ceftobiprole against most common microorganism. Summary of published in vitro studies
Microorganism Number of isolates MIC0 MIC90 References
MS Staphylococcus aureus 7433 0.25–0.5 0.125–2 11,12,15,17,18,20,21
MR S. aureus 6553 0.5–2 0.12–4 11,12,15,17,18,20–22
MS coagulase negative staphylococci 965 0.12–1 0.015–1 11,18,20,21
MR coagulase negative staphylococci 3161 1 1–2 11,18,20–22
Enterococcus faecalis 2958 0.5 2–4 15,20,21
E. faecium (ampicillin MIC  8 µg/mL) 16 4 8 15
E. faecium (ampicillin MIC  16 µg/mL) 20 32 32 20
Penicillin-susceptible Streptococcus pneumoniae 3176 0.008–0.016 0.008–0.25 15,18,20,21,29
Penicillin-intermediate S. pneumoniae 265 0.06 0.12–0.5 18,20,29
Penicillin-resistant S. pneumoniae 1107 0.25–0.5 0.25–2 15,18,20,21,29
Moraxella catarrhalis 230 0.06–0.12 0.12–1 15,20,21
Haemophilus influenzae 1382 0.06–0.125 0.06–1 13,15,20,21
Neisseria gonorrhoeae 51 0.03 0.06–0.12 15,20
N. meningitidis 24 0.002 0.004 20
ESBL-negative Escherichia coli 1172 0.03–0.06 0.06 15,18,20
ESBL-positive E. coli 466 4–32 8–32 15,18,20,21
ESBL-negative Klebsiella pneumoniae 766 0.03–0.125 0.06–0.25 13,15,18,20
ESBL-positive K. pneumoniae 244 4–64 32–128 13,15,18,20
AmpC-negative Citrobacter freundii 368 0.06 1 18
AmpC-positive C. freundii 19 2 32 18
AmpC-negative Enterobacter cloacae 286 0.06 4 18
AmpC-positive E. cloacae 120 8 32 18
Proteus mirabilis 449 0.06 0.06–0.12 15,20,21
ESBL-negative P. vulgaris 427 0.03 0.06 18
ESBL-positive P. vulgaris 16 32 32 18
Morganella morganii 15 0.06 0.12 15
Serratia species 582 0.06–0.06 1–8 20,21
Imipenem susceptible Acinetobacter species 220 0.5 32 18
Imipenem non-susceptible Acinetobacter species 58 32 32 18
Burkholderia cepacia 22 8 64 14,20
Pseudomonas aeruginosa 2741 2–8 8–32 12–14,20,21,32
Ceftazifime-resistant P. aeruginosa 17 16 64 15
Stenotrophomonas maltophilia 32 32–64 32–64 14
Bacteroides fragilis 212 8–16 32–128 12,15,20,34,35
Clostridium species 77 0.125–2 0.25–64 12,20,35
C. difficile 30 4 8 34
C. perfringens 30 0.016 0.016 34
Peptostreptococcus species 59 0.25 32 35
P. anaerobius 30 1–2 4–32 12,34
Finegoldia magna 50 0.12–0.25 0.25–0.5 12,34
Fusobacterium species 34 0.12 8 35
F. nucleatum 50 0.016 0.016 34
Prevotella species 44 0.12 128 35
P. bivia 47 4–16 64 12,34
Abbreviations: MIC, minimum inhibitory concentration; MS, methicillin susceptible; MR, methicillin resistant.Infection and Drug Resistance 2010:3 
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staphylococci from patients with bone and joint infection. 
Ceftobiprole has been shown to be uniformly active 
against the major epidemic MRSA clones, against highly 
oxacillin-resistant strains, against MRSA isolates with 
reduced susceptibility to vancomycin, and against MRSA 
strains carrying the enterococcal vancomycin resistance 
gene complex.23,24 Several studies25,26 have tested the activ-
ity of ceftobiprole against community-associated MRSA 
(CA-MRSA) (including the USA 300 strain) showing MIC50 
and MIC90 values of 1 µg/mL.
Based on its in vitro activity, ceftobiprole may have 
sufficient activity to be efficacious in human infections 
caused by S. aureus and CNS, including those caused by 
methicillin- and vancomycin-resistant isolates.
Enterococcus species
Ceftobiprole has been shown to be equivalent to ampicillin 
in activity against ampicillin-susceptible Enterococcus fae-
calis (ampicillin MIC50 and MIC90 2 and 4 µg/mL, respec-
tively, and ceftobiprole MIC50 and MIC90 0.5 and 4 µg/mL, 
respectively) and E. faecium (ampicillin MIC50 and MIC90 of 
8 µg/mL and ceftobiprole MIC50 and MIC90 4 and 8 µg/mL, 
respectively).15 However, ceftobiprole lacks affinity against 
ampicillin-resistant enterococci as a result of poor affinity 
for PBP5, which is mutated and overexpressed in ampicillin-
resistant enterococci.20,27 All beta-lactamase-producing and 
vancomycin-resistant isolates were inhibited at concentrations 
of 1 µg/mL using a standard inoculum in a study.28 High-
level resistance to aminoglycosides did not affect the in vitro 
activity of ceftobiprole.28
In summary, ceftobiprole has shown in vitro bactericidal 
activity against ampicillin-susceptible enterococci, but 
has only modest activity against ampicillin-resistant 
E. faecium.
Streptococcus pneumoniae
The incidence of pneumococci resistant to penicillin and other 
beta-lactam antimicrobial agents, as well as non-beta-lactam 
antimicrobial agents, has increased worldwide at an alarming 
rate. It has been shown that ceftobiprole was highly active 
against penicillin-susceptible isolates of S. pneumoniae 
(MIC90, 0.03 µg/mL).15 Ceftobiprole was active against 299 
drug-susceptible and -resistant pneumococci, with MIC50 and 
MIC90 values of 0.016 and 0.016 µg/mL (penicillin-susceptible 
isolates), 0.06 and 0.5 µg/mL (penicillin-intermediate iso-
lates) and 0.5 and 1.0 µg/mL (penicillin-resistant isolates), 
respectively.29 Ceftobiprole MICs against S. pneumoniae 
were lower than those of ceftriaxone and cefuroxime in two 
worldwide surveillance studies.18,21 As with ceftriaxone and 
cefuroxime, ceftobiprole MICs increased with increasing 
resistance to penicillin, but even among penicillin-resistant 
isolates, ceftobiprole MICs did not exceed 1 mcg/mL. It 
has been described that beta-lactam MIC values correlated 
closely with increases in the numbers of PBP1a, PBP2x and 
PBP2b substitutions.30 Alpha- and beta-hemolytic strepto-
cocci have been shown to have low ceftobiprole MICs in 
several studies.15,20,21
Penicillin-susceptible, -intermediate and -resistant 
isolates of S. pneumoniae are highly susceptible to ceftobi-
prole in vitro. Ceftobiprole may therefore be a therapeutic 
option for infections caused by pneumococci that are resistant 
to conventional cephalosporins. This renders ceftobiprole a 
promising candidate for empirical treatment of community- 
and hospital-acquired pneumonia.
Moraxella catarrhalis  
and Haemophilus influenzae
Ceftobiprole had MIC values 0.5 and 0.03 µg/mL for 
40 beta-lactamase-producing and 9 beta-lactamase-non 
producing clinical isolates of Moraxella catarrhalis, 
respectively.10 Similar results were found in other studies.15,20 
Ceftobiprole MIC50 and MIC90 values for 321 clinical 
isolates of H. influenzae were 0.06 and 0.25 µg/mL for 262 
beta-lactamase-positive isolates, 0.03 and 0.25 µg/mL for 
40 beta-lactamase-negative isolates, and 0.5 and 2.0 mcg/ml 
for 19 beta-lactamase-negative ampicillin-resistant isolates, 
respectively.10 Ceftriaxone MIC values for H. influenzae 
were usually at least 2-fold lower than those of ceftobiprole, 
whereas MIC values of amoxicillin (with or without 
clavulanate) were usually 2- to 4-fold higher than those 
of ceftobiprole. Cefpodoxime MIC values were similar 
to or slightly higher than those of ceftobiprole.10 Similar 
results were found in other studies.13,15 Results of these 
studies, combined with the excellent in vitro activity of 
ceftobiprole against S. pneumoniae and M. catarrhalis, make 
ceftobiprole a promising drug for the treatment of patients 
with community-acquired respiratory tract infections who 
require hospitalization.
Enterobacteriaceae
Ceftobiprole appears to have a unique pattern of Gram-
negative PBP affinity. The major targets for ceftobiprole in 
E. coli appear to be PBP1b and PBP2, and not PBP3 (the target 
for ceftriaxone and other third-generation cephalosporins). 
High affinity for PBP2 appears to be a general, novel property 
of the pyrrolidinone-3-ylidenemethyl cephems. PBP affinities Infection and Drug Resistance 2010:3 9
Focus on ceftobiprole Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
to and stability with different classes of beta-lactamases 
determine the antibacterial spectrum of ceftobiprole against 
Gram-negative pathogens. As with 3rd- and 4th-generation 
extended-spectrum cephalosporins, ceftobiprole was largely 
inactive against strains expressing ESBL enzymes. A lack of 
activity against P . vulgaris (MIC50 and MIC90 32 µg/mL) 
results from efficient enzymatic hydrolysis (mediated by K1 
beta-lactamase) of ceftobiprole by this microorganism. Cefto-
biprole had similar in vitro activity to ceftriaxone against dif-
ferent isolates of Gram-negative Enterobacteriaceae.15 These 
results are consistent with those reported in other studies.12,13,20 
Ceftobiprole showed more activity than ceftriaxone against 
Citrobacter freundii and against Enterobacter cloacae.20,31 
This appears to be the result of relatively high-level stability 
toward broad-spectrum class A beta-lactamases produced by 
these two microorganisms. Ceftobiprole is more labile than 
cefepime to ESBLs; as a consequence, its inhibitory activity 
against ESBL-producing isolates is weaker. As shown in 
two in a surveillance studies,18,21 ceftobiprole was similar 
in potency to the third- and fourth-generation cephems 
for the principle members of the Enterobacteriaceae. The 
decreased level of activity of both cefepime and ceftobip-
role against ceftazidime non-susceptible and derepressed 
AmpC screen-positive isolates of E. cloacae and Citrobacter 
spp. is likely a reflection of their relative stability to class 
C beta-lactamases. As with other cephalosporins, the in vitro 
activity of ceftobiprole against ESBL screen-positive strains 
of E. coli, Klebsiella pneumoniae and Pseudomonas mirabilis 
was notably diminished. This finding is consistent with 
other studies and likely reflects the increased susceptibility 
of ceftobiprole and other cephalosporins to hydrolysis by 
mutated class A beta-lactamases (TEM- and SHV-type 
enzymes). Ceftobiprole was among the most active agents 
tested (MIC90, 0.06 µg/mL) against Salmonella spp., 
Shigella spp. and Vibrionaceae.15,20,21
Pseudomonas aeruginosa  
and other non-fermenting  
Gram-negative bacilli
Ceftobiprole appears to have in vitro antipseudomonal 
activity resembling that of cefepime, at least against isolates 
susceptible to ceftazidime.15 The presence of ceftobiprole’s 
7-aminothiadiazolylhydroxyimino side chain cannot 
explain this activity because most cephalosporins bearing 
this substituent do not inhibit P . aeruginosa. This finding 
suggests that the positively charged 3 substituent may 
contribute to the antipseudomonal activity of ceftobiprole. 
However, cross-resistance between ceftazidime, cefepime, 
and ceftobiprole exists for most, but not all, P . aeruginosa 
isolates.15,32 Ceftobiprole MIC90 values of 8 to 16 µg/mL for 
ceftazidime-susceptible P . aeruginosa, while MIC90 values 
of 16 to 64 µg/mL for ceftazidime-resistant isolates have 
been reported.12,13,15,20 In the surveillance study published 
by Fristche et al21 ceftobiprole was equal in potency to 
ceftazidime and 2-fold more potent than cefepime against 
P . aeruginosa. Pillar et al18 reported that, as was observed 
with Enterobacteriaceae, the activity of ceftobiprole and 
cefepime against P. aeruginosa and Acinetobacter spp. 
was also dependent on the expression of beta-lactam 
resistance. MICs of both ceftobiprole and cefepime 
increased significantly among ceftazidime non-susceptible 
P. aeruginosa. The activity of ceftobiprole against other 
nonfermenting Gram-negative bacilli tested was most similar 
to that of imipenem in terms of MIC50 and MIC90 values 
in a study.14 Ceftobiprole was particularly active against 
Agrobacterium radiobacter (MIC90, 0.25 µg/mL), Alcaligenes 
faecalis (MIC90, 2 µg/mL), Bordetella bronchiseptica 
(MIC90, 4 µg/mL), Ochrobactrum anthropi (MIC90, 2 µg/mL), 
Pseudomonas oryzihabitans (MIC90, 0.25 µg/mL), Ralstonia 
pickettii  (MIC90,  4  µg/mL)  and  Weeksella  virosa 
(MIC90, 2 µg/mL). Imipenem, however, had superior 
activity against Achromobacter xylosoxidans, Acinetobacter 
baumannii, Brevundimonas vesicularis, Burkholderia 
cepacia complex, Comamonas acidovorans, P . aeruginosa 
and Pseudomonas stutzeri. Cefepime was more active against 
Chryseobacterium indologenes, Sphingomonas species 
and P. aeruginosa. Ceftobiprole MIC50 and MIC90 values 
of 2 to 32 and 16 to 32 µg/mL have been reported for 
Acinetobacter baumannii species,14,16 and MIC50 and MIC90 
values of 0.06 for Acinetobacter lwoffii.16
Ceftobiprole is largely inactive against Stenotrophomonas 
maltophilia, Burkholderia cepacia and Chryseobacterium 
meningosepticum.14,33
Based on in vitro studies, ceftobiprole may be potent 
enough to be of clinical utility against most of the species 
evaluated apart from S. maltophilia and C. meningosepticum. 
Ceftobiprole appears to have similar in vitro activity to 
ceftazidime and cefepime against ceftazidime-susceptible 
P. aeruginosa (although ceftobiprole MIC values may be 
a dilution higher than those of ceftazidime and cefepime in 
some cases). Ceftobiprole lacks activity against ceftazidime-
resistant P . aeruginosa isolates.
Anaerobic bacteria
Ceftobiprole had good activity against a wide range of Gram-
positive and -negative anaerobes isolated from diabetic foot Infection and Drug Resistance 2010:3 10
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infections.12 In this study, all Propionibacterium acnes isolates 
had MIC values 0.25 µg/mL. Clostridium species had MIC 
values 1 µg/mL (except for one isolate of Clostridium 
innocuum and one isolate of Clostridium clostridioforme). 
Ceftobiprole activity against Clostridium species has species 
variability with Clostridium perfringens typically having low 
MIC values.34,35 Peptostreptococci had MIC values 1 µg/mL 
with the exception of 10 isolates of Peptostreptococcus 
anaerobius (MIC90, 4 µg/mL).12,34 However, Wootton et al35 
reported MIC90 of 32 µg/mL for Peptostreptococcus species. 
Ceftobiprole has been highly active against Finegoldia magna 
isolates (MIC90,  0.5 µg/mL).12,34 Ceftobiprole has been 
shown active (MIC  0.016–4 µg/mL) against Gram-positive 
beta-lactamase-negative isolates (other than C. difficile and 
P . anaerobius isolates) and against Fusobacterium nucleatum 
(including both beta-lactamase-positive and -negative 
isolates).34 Wootton et al35 reported higher MIC values for 
Fusobacterium species, including F. nucleatum, F. russi, 
F. necroforum and F. mortiferum (MIC90, 8 µg/mL). Cefto-
biprole’s activity against Gram-negative anaerobes is species 
dependent.12 While Porphyromonas asaccharolytica and 
Porphyromonas somerae had MIC values 0.125 µg/mL, 
Prevotella bivia and Prevotella melaninogenica had higher 
MIC values (64 and 16 µg/mL, respectively).12,34,35 High 
MIC values of ceftobiprole (32 µg/mL) have been 
reported for Bacteroides fragilis group, possibly due to 
chromosomal beta-lactamase activity. MIC90 values against 
non-fragilis Bacteroides species of 32 µg/mL have also 
been reported.34,35
These studies indicate that ceftobiprole is active against 
many Gram-positive anaerobes in vitro. Its activity against 
Gram-negative anaerobes is species-dependent, being less 
active against the majority of beta-lactamase–producing 
Gram-negative anaerobes. The activity of ceftobiprole 
against F. nucleatum and C. perfringens may be useful 
in the empirical treatment of complicated skin and skin 
structure infections as well as oropharyngeal abscesses 
and aspiration pneumonia (although it has limited activity 
against Prevotella species). However, its poor activity against 
Bacteroides species is a limitation for empirical treatment of 
intra-abdominal infections.
Resistance studies
In an in vitro study, ceftobiprole was refractory to hydrolysis 
by the common staphylococcal PC1 beta-lactamase, the 
class TEM-1 beta-lactamase, and the class C AmpC beta-
lactamase, but was labile to hydrolysis by class B, class D, 
and class A ESBL.36 Experiments involving prolonged serial 
transfer of staphylococci in the presence of subinhibitory 
concentrations of ceftobiprole or comparators and assessing 
single-step mutation frequencies suggest that staphylococci 
are relatively refractory to development of endogenous 
resistance to ceftobiprole.37 Serial passage with increasing 
concentrations of ceftobiprole performed with 3 MRSA 
isolates and 1 MSSA isolate suggests that development of 
resistance to ceftobiprole due to chromosomal mutations 
occurs with low frequency, if ever, in MRSA.15 However, a 
recent study38 demonstrated that MRSA can develop high-
level ceftobiprole resistance in vitro mediated by mutations in 
PBP2a. Ceftobiprole did not select for S. pneumoniae clones 
with MIC values exceeding 1 mcg/ml during up to 50 days 
serial passage in the presence of subinhibitory concentra-
tions of ceftobiprole, and single-passage selection experi-
ments showed varying rates of endogenous emergence of 
resistance to ceftobiprole from 1.7 × 10–3 to 1.2 × 10–8, at 
the MIC to 1.4 × 10–8 to 1 × 10–9 at 8 times the MIC.29 
Ceftobiprole is a poor substrate for class C beta-lactamases 
and is hydrolyzed at very low rates compared to cephalo-
thin or penicillin G. It is more readily hydrolyzed by class 
A cephalosporinase from P . vulgaris and by ESBLs (TEM 
derivatives). In Enterobacteriaceae, ceftobiprole, cefepime 
and ceftazidime generally cause less induction of AmpC 
beta-lactamases than cefoxitin and imipenem. Ceftobiprole 
is not readily hydrolyzed by AmpC enzymes, suggesting that 
transient induction of AmpC enzymes may not be a major 
contributing factor to resistance among Gram-negative bac-
teria.36 Finally, to date, emergence of ceftobiprole resistance 
has not been reported in animal or human studies. However 
this is an issue that deserves careful monitoring.
Ceftobiprole in experimental 
animal models
In keeping with its in vitro activity, ceftobiprole medocaril 
showed activity in an experimental mouse septicemia model 
against a variety of pathogens (MSSA, MRSA, S. pyogenes, 
S. pneumoniae, E. coli, K. pneumoniae, C. freundii, 
S. marcescens and P . mirabilis).15 Against the MRSA strain, 
ceftobiprole was superior to vancomycin. Ceftobiprole 
medocaril was superior to ceftriaxone and vancomycin against 
MSSA. Ceftobiprole medocaril showed in vivo activity 
against three penicillin-resistant strains of S. pneumoniae, 
including a strain with reduced in vitro susceptibility to 
third-generation cephalosporins. Ceftobiprole medocaril 
exhibited good in vivo activity against group A streptococci 
and E. coli. Ceftobiprole medocaril was more active than 
vancomycin and linezolid against the vancomycin-susceptible Infection and Drug Resistance 2010:3 11
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strain in an experimental S. aureus mouse abscess model.15 
Ceftobiprole medocaril was also active against VISA, as this 
pathogen was eliminated from most animals. Ceftobiprole 
medocaril was more active than vancomycin or amoxicillin-
clavulanic acid against MRSA in a rat experimental endocar-
ditis model.37 Ceftobiprole medocaril and vancomycin were 
equally active in a rabbit model of aortic valve endocarditis 
against MRSA, whereas ceftobiprole medocaril was more 
active than vancomycin against a VISA strain.39 No differ-
ence was found between animals treated with ceftobiprole 
medocaril and those treated with vancomycin in a rat tissue 
cage model of chronic MRSA foreign-body infection.40 No 
differences were found in the microbiological cure among 
4 weeks treatment with ceftobiprole medocaril, vancomycin 
or linezolid in a rabbit model of MRSA tibial osteomyeli-
tis.41 Ceftobiprole medocaril had comparable activity to that 
of ampicillin against four strains of E. faecalis (including 
beta-lactamase producing and vancomycin resistant strains 
in a mouse peritonitis model).42 In an immunocompetent 
murine pneumonia model, ceftobiprole medocaril activ-
ity was similar to that of ceftriaxone and cefepime against 
H. influenzae and ESBL-nonproducing strains of E. cloacae 
and K. pneumoniae. For ESBL-producing K. pneumoniae, no 
differences were detected between no treatment and treatment 
with ceftobiprole medocaril, ceftriaone or cefepime.43
These models confirm the in vivo activity of ceftobiprole 
against Gram-negative bacteria (except for ESBL-producing 
Gram-negative bacilli and P. vulgaris). There are limited 
published experimental animal trials evaluating ceftobiprole’s 
activity against P . aeruginosa.
Pharmacokinetic profile
Because ceftobiprole is not sufficiently soluble in water to 
be used for parenteral administration in humans, it is admin-
istered as a water-soluble prodrug, ceftobiprole medocaril. 
Ceftobiprole medocaril is rapidly converted by plasma 
esterases to ceftobiprole. The safety and pharmacokinetics 
of ceftobiprole medocaril were evaluated in a double-blind, 
single ascending-dose study (following doses of 125, 250, 
500, 750 or 1000 mg) in 40 healthy male subjects. Peak 
levels of the active drug in plasma were observed at the 
end of the 30-min infusion. Afterwards, concentrations in 
plasma declined in a biphasic manner consistent with a rapid 
distribution of ceftobiprole from the systemic circulation 
into other body compartments. The apparent volume of 
distribution (18–20 L) was similar to the values reported for 
other beta-lactams. The clearance (4.1–5.1 L/h), volume of 
distribution (18–20 L), and half-life in the post-distribution 
phase (3 hours) remained constant over the dose range.44 
Results of a multiple-dose study indicate that ceftobiprole 
has stable pharmacokinetic properties over an 8-day course 
of dosing, with low intersubject variability.45 Overall results 
agreed with data reported by the same group in a single 
ascending-dose study. A strong correlation between the time 
that the concentration remains above the MIC (T  MIC) 
and effect has been demonstrated in both in vitro and experi-
mental animal model studies.46,47 In a single-dose study per-
formed following infusion of ceftobiprole medocaril at 500 
and 1000 mg, total concentrations were above the MIC of 4 
Bacteroides for 5 to 7 hours, corresponding to a T  MIC 
of 42% to 58% of a 12-hour interval, assuming twice-daily 
dosing, for 500 and 1000 mg, respectively.44 For ceftobi-
prole medocaril 500 mg every 12 hours, the probabilities 
of achieving 30% and 50% T  MIC exceeded 90% for 
MIC values of 2 mcg/ml and 1 µg/mL, respectively. 
And for ceftobiprole medocaril 500 mg every 8 hours, the 
probabilities of achieving 40 and 60% T  MIC exceeded 
90% for MIC values of 4 µg/mL and 2 µg/mL, respec-
tively. For both regimens, the probability of achieving a 
near bactericidal effect (50% T  MIC in Gram-positive 
and 60% in Gram-negative microorganisms) exceeded 
90% for MSSA and MRSA and non-AmpC–producing 
Gram-negative microorganisms.48 The skin and skin struc-
ture infections regimen (ceftobiprole medocaril 500 mg 
intravenously every 12 hours) and nosocomial pneumonia 
regimen (ceftobiprole medocaril 500 mg intravenously 
every 8 hours) both demonstrated a high probability of 
achieving a maximal bactericidal effect against both MSSA 
and MRSA isolates. When mixed infections containing 
both gram-negative and gram-positive microorganisms 
are suspected, a regimen of 500 mg intravenously every 8 
hours may be appropriate.49 Although lung concentrations 
of ceftobiprole have not been measured in humans, a study 
in leukopenic female Swiss albino mice demonstrated lower 
lung than serum concentrations of ceftobiprole but a longer 
ceftobiprole half-life in lungs versus serum.50 Ceftobiprole 
is predominantly eliminated in the urine.44 The highest urine 
drug concentrations are observed within 2 hours after the 
start of the infusion, and urine concentrations correlate with 
dose. Glomerular filtration of the active metabolite appears 
to be predominantly responsible for removal of free drug 
from the systemic circulation.44 Lodise et al48 analyzed a 
total of 150 Phase I/II subjects in order to determine the 
optimal renal dose adjustment for intravenous ceftobiprole 
medocaril. Ceftobiprole medocaril 500 mg intravenously 
every 12 hours was determined to be the most appropriate Infection and Drug Resistance 2010:3 12
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regimen for those with a CrCl  50 mL/min. Dosing for 
patients receiving hemodialysis/hemofiltration remains to be 
addressed in the published literature. Ceftobiprole medocaril 
is not hepatically metabolized.
Post-antibiotic effect
It has been described that the effect of sub-MIC concentra-
tions on growth during the post-antibiotic effect (PAE) was 
longer than the PAE in a study,51 suggesting that continued 
exposure to sub-MIC levels of ceftobiprole following a 
supra-inhibitory level may allow for continued suppression 
of growth in vivo. The mean PAE for 3 S. pneumoniae was 
1.8 h (range 1.4–3.1 hours) and did not differ by penicil-
lin susceptibility.51 Staphylococcal PAEs were slightly 
lower for methicillin-susceptible isolates (mean, 0.4 hours; 
range, 0–0.8 hours) than for methicillin-resistant isolates 
(mean, 1.0 hours; range, 0–1.8 hours). The PAEs for the 
vancomycin-susceptible isolates (mean, 0.6 hours; range, 
0–1.1 hours) did not differ from those for vancomycin-
intermediate and -resistant isolates (mean, 1.0 hours; range, 
0–1.8 hours). Three E. faecalis isolates had a mean PAE of 
0.4 hours (0–0.9 hours). These findings support the twice-
daily dosing of ceftobiprole for infections caused by Gram-
positive cocci.
Adverse events
In the Schmitt-Hoffmann studies,44,45 8 subjects dosed with 
ceftobiprole experienced 10 adverse effects. Of these, 7 were 
reported as mild taste disturbances, described by subjects as 
a caramel-like taste experienced during the infusion period 
(attributed to conversion of the prodrug to ceftobiprole 
plus diacetyl, the latter being a natural product which has 
a caramel-like taste). The remaining 3 adverse effects were 
mild nausea (2 subjects) and moderate vomiting (1 subject). 
None of the adverse effects were severe or serious, and none 
required treatment.
Clinical studies
Two recently published multicenter non-inferiority tri-
als involving more than 1500 patients with skin and soft 
tissue infections have shown cure rates similar to those 
of the comparators (vancomycin or vancomycin plus cef-
tazidime). The Study of Resistant S. aureus Skin and Skin 
Structure Infections (STRAUSS) trial3 was a multicenter, 
randomized, double-blind clinical trial involving patients 
with complicated skin and skin structure infections in 
whom Gram-positive pathogens were documented and/or 
suspected based on microscopic examination. The primary 
objective was to compare clinical cure rates 7 to 14 days after 
completion of therapy with ceftobiprole medocaril (500 mg 
intravenously every 12 h) or vancomycin (1 g intravenously 
every 12 hours). The predominant pathogen was S. aureus 
(37% of which were MRSA). The Gram-negative isolates 
included Enterobacteriaceae (37), Pseudomonas species (6) 
and A. baumannii (2). Overall cure rates in the ceftobiprole-
treated (n = 282) and vancomycin-treated (n = 277) subjects 
in the clinically evaluable population were similar (93.3% 
and 93.5%, respectively). Cure rates in the ceftobiprole-
treated (n = 61) and vancomycin-treated (n = 60) subjects 
in the clinically evaluable population with MRSA infections 
were 91.8% and 90.0%, respectively. Serious treatment-
related adverse events were 1% in the ceftobiprole-treated 
group and 3% in the vancomycin-treated group. Rates of 
therapy discontinuation due to treatment-related adverse 
events were comparable in the two groups.
A second ceftobiprole phase III skin and skin structure 
infection double-blind study (STRAUSS 2) reportedly 
enrolled 828 patients who were either treated with ceftobip-
role medocaril or the combination of ceftazidime plus van-
comycin (2:1 randomization).2 In this study, approximately 
one-third of patients had diabetic foot infections. A total 
of 91% of clinically evaluable patients were cured with 
ceftobiprole medocaril compared to 90% of patients treated 
with combination therapy. The clinical response in those 
with diabetic foot infection was 86% and 82% for ceftobi-
prole medocaril versus combination therapy, respectively. 
More than 20% of microbiologically evaluable patients had 
MRSA infections. A phase III clinical trial for nosocomial 
pneumonia (CHOPIN) has also been completed but results 
have not been published; a trial for community acquired 
pneumonia is ongoing.
Conclusions
MRSA has assumed increased importance in both com-
munity-acquired and nosocomial infections. A broad-
spectrum agent with bactericidal activity against MRSA 
is an attractive treatment option. Ceftobiprole medocaril 
is a broad-spectrum cephalosporin with in vitro activity 
against MRSA that has demonstrated favorable results in 
two phase III trials in complicated skin and skin structure 
infections which included subjects with MRSA infec-
tions. Ceftobiprole exhibits in vitro activity against many 
bacteria that cause hospital- and community-acquired 
infections, including methicillin-resistant staphylococci. It 
has activity against S. aureus, including MRSA and VISA, 
CNS, Enterococcus species (but not ampicillin-resistant Infection and Drug Resistance 2010:3 13
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enterococci), pneumococci and some anaerobes; it also 
has activity against Gram-negative bacilli similar to that 
of available third- and fourth-generation cephalosporins. 
Ceftobiprole appears to be relatively refractory to 
development of endogenous resistance. Ceftobiprole is not 
active against ESBL-producing Gram-negative bacilli or 
P. vulgaris, and its activity against P. aeruginosa has not 
yet been adequately evaluated in vivo. Ceftobiprole has 
received fast-track status from the FDA; further clinical 
studies are warranted to evaluate its efficacy and safety 
in patients with infections beyond those of skin and skin 
structures.
Disclosures
The authors disclose no conflicts of interest.
References
  1.  Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in 
development, with a focus on ceftobiprole: the first anti-MRSA beta-
lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs. 
2007;16(4):419–429.
  2.  Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-
blind trial comparing ceftobiprole medocaril with vancomycin plus 
ceftazidime for the treatment of patients with complicated skin and 
skin-structure infections. Clin Infect Dis. 2008;46(5):647–655.
  3.  Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. 
Results of a double-blind, randomized trial of ceftobiprole treat-
ment of complicated skin and skin structure infections caused by 
gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1): 
37–44.
  4.  El Solh A. Ceftobiprole: a new broad spectrum cephalosporin. Expert 
Opin Pharmacother. 2009;10(10):1675–1686.
  5.  Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. 
Bactericidal activity of BAL9141, a novel parenteral cephalosporin 
against contemporary Gram-positive and Gram-negative isolates. Diagn 
Microbiol Infect Dis. 2004;50(1):73–75.
  6.  Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Binding 
of ceftobiprole and comparators to the penicillin-binding proteins of 
Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, 
and Streptococcus pneumoniae. Antimicrob Agents Chemother. 
2007;51(7):2621–2624.
  7.  Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. 
Use of Monte Carlo simulations to select therapeutic doses and pro-
visional breakpoints of BAL9141. Antimicrob Agents Chemother. 
2004;48(5):1713–1718.
  8.  Clinical and Laboratory Standards Institute. Performance standards 
for antimicrobial susceptibility testing. 17th informational supple-
ment. CLSI document M100-S17 [ISBN 1-56238-625-5]. Clinical and 
Laboratory Standards Institute, Wayne, PA, USA, 2007.
  9.  Anderegg TR, Jones RN, Sader HS. Quality control guidelines for 
BAL9141 (Ro 63–9141), an investigational cephalosporin, when refer-
ence MIC and standardized disk diffusion susceptibility test methods 
are used. J Clin Microbiol. 2004;42(7):3356–3358.
  10.  Bogdanovich T, Clark C, Ednie L, et al. Activities of ceftobiprole, a 
novel broad-spectrum cephalosporin, against Haemophilus influen-
zae and Moraxella catarrhalis. Antimicrob Agents Chemother. Jun 
2006;50(6):2050–2057.
  11.  Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylo-
coccal activity of ceftobiprole, a new broad-spectrum cephalosporin. 
Antimicrob Agents Chemother. 2005;49(10):4210–4219.
  12.  Goldstein EJ, Citron DM, Merriam CV , Warren YA, Tyrrell KL, Fernan-
dez HT. In vitro activity of ceftobiprole against aerobic and anaerobic 
strains isolated from diabetic foot infections. Antimicrob Agents Che-
mother. 2006;50(11):3959–3962.
  13.  Issa NC, Rouse MS, Piper KE, Wilson WR, Steckelberg JM, Patel R. 
In vitro activity of BAL9141 against clinical isolates of gram-negative 
bacteria. Diagn Microbiol Infect Dis. 2004;48(1):73–75.
  14.  Zbinden R, Punter V, von Graevenitz A. In vitro activities of 
BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, 
against gram-negative nonfermenters. Antimicrob Agents Chemother. 
2002;46(3):871–874.
  15.  Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. 
In vitro and in vivo properties of Ro 63–9141, a novel broad-spectrum 
cephalosporin with activity against methicillin-resistant staphylo-
cocci. Antimicrob Agents Chemother. 2001;45(3):825–836.
  16.  Jones ME. In-vitro profile of a new beta-lactam, ceftobiprole, with 
activity against methicillin-resistant Staphylococcus aureus. Clin 
Microbiol Infect. 2007;13 Suppl 2:17–24.
  17.  von Eiff C, Friedrich AW, Becker K, Peters G. Comparative in vitro 
activity of ceftobiprole against staphylococci displaying normal and 
small-colony variant phenotypes. Antimicrob Agents Chemother. 
2005;49(10):4372–4374.
  18.  Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of 
ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive 
and gram-negative isolates of European origin. J Antimicrob Chemother. 
2008;61(3):595–602.
  19.  Srinivasan V, McGowan JE Jr, McAllister S, Tenover FC. In vitro 
activity of ceftobiprole against coagulase-negative staphylococci 
isolated in the USA. Int J Antimicrob Agents. 2008;31(3):294–296.
  20.  Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro 
evaluation of BAL9141, a novel parenteral cephalosporin active 
against oxacillin-resistant staphylococci. J Antimicrob Chemother. 
2002;50(6):915–932.
  21.  Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, 
a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, 
tested against contemporary pathogens: results from the SENTRY 
Antimicrobial Surveillance Program (2005–2006). Diagn Microbiol 
Infect Dis. 2008;61(1):86–95.
  22.  Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, 
daptomycin, linezolid, and vancomycin against methicillin-resistant 
staphylococci associated with endocarditis and bone and joint infection. 
Diagn Microbiol Infect Dis. 2007;58(3):363–365.
  23.  Chung M, Antignac A, Kim C, Tomasz A. Comparative study 
of the susceptibilities of major epidemic clones of methicillin-
resistant Staphylococcus aureus to oxacillin and to the new broad-
spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother. 
2008;52(8):2709–2717.
  24.  Lin G, Appelbaum PC. Activity of ceftobiprole compared with those 
of other agents against Staphylococcus aureus strains with differ-
ent resistotypes by time-kill analysis. Diagn Microbiol Infect Dis. 
2008;60(2):233–235.
  25.  Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, line-
zolid, vancomycin, and daptomycin against community-associated 
and hospital-associated methicillin-resistant Staphylococcus aureus. 
Antimicrob Agents Chemother. 2008;52(8):2974–2976.
  26.  Yun HC, Ellis MW, Jorgensen JH. Activity of ceftobiprole against 
community-associated methicillin-resistant Staphylococcus aureus 
isolates recently recovered from US military trainees. Diagn Microbiol 
Infect Dis. 2007;59(4):463–466.
  27.  Deshpande LM, Jones RN. Bactericidal activity and synergy studies 
of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested 
against streptococci, enterococci and methicillin-resistant staphylococci. 
Clin Microbiol Infect. 2003;9(11):1120–1124.
  28.  Arias CA, Singh KV , Panesso D, Murray BE. Time-kill and synergism 
studies of ceftobiprole against Enterococcus faecalis, including beta-
lactamase-producing and vancomycin-resistant isolates. Antimicrob 
Agents Chemother. 2007;51(6):2043–2047.Infection and Drug Resistance 2010:3
Infection and Drug Resistance
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/infection-and-drug-resistance-journal
Infection and Drug Resistance is an international, peer-reviewed open-
access journal that focuses on the optimal treatment of infection (bacte-
rial, fungal and viral) and the development and institution of preventive 
strategies to minimize the development and spread of resistance. The 
journal is specifically concerned with the epidemiology of antibiotic 
resistance and the mechanisms of resistance development and diffusion 
in both hospitals and the community. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
14
Bustos and Del Pozo Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  29.  Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of 
ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents 
Chemother. 2005;49(5):1932–1942.
  30.  Davies TA, Shang W, Bush K. Activities of ceftobiprole and other 
beta-lactams against Streptococcus pneumoniae clinical isolates from 
the United States with defined substitutions in penicillin-binding 
proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother. 
2006;50(7):2530–2532.
  31.  Hecker SJ, Cho IS, Glinka TW, et al. Discovery of MC-02,331, a new 
cephalosporin exhibiting potent activity against methicillin-resistant 
Staphylococcus aureus. J Antibiot (Tokyo). 1998;51(8):722–734.
  32.  Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. 
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas 
aeruginosa obtained from Canadian intensive care unit (ICU) patients 
as part of the CAN-ICU Study. J Antimicrob Chemother. 2008;62(1): 
206–208.
  33.  Thamlikitkul V, Trakulsomboon S. In vitro activity of ceftobiprole 
against Burkholderia pseudomallei. J Antimicrob Chemother. 
2008;61(2):460–461.
  34.  Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of 
ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol 
Infect Dis. 2007;58(1):133–136.
  35.  Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL 9141, a new 
broad-spectrum pyrrolidinone cephalosporin: activity against clinically 
significant anaerobes in comparison with 10 other antimicrobials.   
J Antimicrob Chemother. 2002;49(3):535–539.
  36.  Queenan AM, Shang W, Kania M, Page MG, Bush K. Interactions 
of ceftobiprole with beta-lactamases from molecular classes A to D. 
Antimicrob Agents Chemother. 2007;51(9):3089–3095.
  37.  Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. 
BAL9141, a novel extended-spectrum cephalosporin active against 
methicillin-resistant Staphylococcus aureus in treatment of experimental 
endocarditis. Antimicrob Agents Chemother. 2002;46(1):171–177.
  38.  Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro 
selection and characterization of ceftobiprole-resistant methicillin-
resistant Staphylococcus aureus. Antimicrob Agents Chemother. 
2008;52(6):2089–2096.
  39.  Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic 
valve endocarditis due to methicillin-resistant and vancomycin-
intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 
2005;49(3):884–888.
  40.  Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP. Intensive 
therapy with ceftobiprole medocaril of experimental foreign-body 
infection by methicillin-resistant Staphylococcus aureus. Antimicrob 
Agents Chemother. 2005;49(9):3789–3793.
  41.  Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. 
Efficacies of ceftobiprole medocaril and comparators in a rabbit model 
of osteomyelitis due to methicillin-resistant Staphylococcus aureus. 
Antimicrob Agents Chemother. 2008;52(5):1618–1622.
  42.  Arias CA, Singh KV , Panesso D, Murray BE. Evaluation of ceftobiprole 
medocaril against Enterococcus faecalis in a mouse peritonitis model. 
J Antimicrob Chemother. 2007;60(3):594–598.
  43.  Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R. Cef-
tobiprole medocaril (BAL5788) treatment of experimental Haemophilus 
influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine 
pneumonia. Diagn Microbiol Infect Dis. 2006;55(4):333–336.
  44.  Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose phar-
macokinetics and safety of a novel broad-spectrum cephalosporin 
(BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 
2004;48(7):2570–2575.
  45.  Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose phar-
macokinetics and safety of a novel broad-spectrum cephalosporin 
(BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 
2004;48(7):2576–2580.
  46.  Craig WA, Andes DR. In vivo pharmacodynamics of ceftobiprole 
against multiple bacterial pathogens in murine thigh and lung infection 
models. Antimicrob Agents Chemother. 2008;52(10):3492–3496.
  47.  Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic charac-
terization of ceftobiprole in experimental pneumonia caused by phe-
notypically diverse Staphylococcus aureus strains. Antimicrob Agents 
Chemother. 2008;52(7):2389–2394.
  48.  Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attain-
ment for ceftobiprole as derived from a population pharmacokinetic 
analysis of 150 subjects. Antimicrob Agents Chemother. 2007;51(7): 
2378–2387.
  49.  Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, 
Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobi-
prole. Diagn Microbiol Infect Dis. 2008;61(1):96–102.
  50.  Azoulay-Dupuis E, Bedos JP, Mohler J, Schmitt-Hoffmann A, 
Schleimer M, Shapiro S. Efficacy of BAL5788, a prodrug of 
cephalosporin BAL9141, in a mouse model of acute pneumo-
coccal pneumonia. Antimicrob Agents Chemother. 2004;48(4): 
1105–1111.
  51.  Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftobiprole 
against 12 Gram-positive organisms. Antimicrob Agents Chemother. 
2006;50(11):3956–3958.